Caroline J Dietz1,2, Hua Sun1,2, William C Yao1, Martin J Citardi1, David B Corry3, Amber U Luong1,2. 1. Department of Otolaryngology-Head and Neck Surgery, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, U.S.A. 2. the Center for Immunology and Autoimmune Diseases, Institute of Molecular Medicine, McGovern Medical School at the University of Texas Health Science Center, Houston, Texas, U.S.A. 3. Department of Medicine and the Biology of Inflammation Center, Baylor College of Medicine, Houston, Texas, U.S.A.
Abstract
OBJECTIVE: In the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP), Aspergillus fumigatus (A. fumigatus) can upregulate IL-33 from human sinonasal epithelial cells (SNECs), which then activates innate lymphoid cells causing release of IL-13, an important driver of allergic inflammation. However, the mechanism by which A. fumigatus mediates the induction of IL-33 expression remains to be elucidated. The objectives of this study were to determine the specific fungal component(s) and the receptor responsible for mediating the A. fumigatus induced increase in IL-33 expression in SNECs from patients with CRSwNP. METHODS: SNECs from CRSwNP patients were cultured and stimulated with various fungal components in the absence or presence of 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, an irreversible serine protease inhibitor, or GB83, a reversible protease activated receptor 2 (PAR2) inhibitor. IL-33 expression was evaluated using quantitative real-time polymerase chain reaction (qRT-PCR). PAR2 expression was examined in inflamed mucosa from nonatopic control and CRSwNP patients. RESULTS: Elevation of IL-33 expression in primary SNECs was found in response to fungal protease but not fungal cell wall components. PAR2 expression was elevated in inflamed mucosa from CRSwNP patients in comparison to controls. The A. fumigatus fungal protease-mediated elevation in IL-33 expression by human SNECs was serine protease- and PAR2-dependent. CONCLUSION: These data suggest that serine protease activity of A. fumigatus is capable of inducing IL-33 expression in CRSwNP SNECs via PAR2, a potential therapeutic target in the treatment of CRSwNP. LEVEL OF EVIDENCE: NA Laryngoscope, 129:2230-2235, 2019.
OBJECTIVE: In the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP), Aspergillus fumigatus (A. fumigatus) can upregulate IL-33 from human sinonasal epithelial cells (SNECs), which then activates innate lymphoid cells causing release of IL-13, an important driver of allergic inflammation. However, the mechanism by which A. fumigatus mediates the induction of IL-33 expression remains to be elucidated. The objectives of this study were to determine the specific fungal component(s) and the receptor responsible for mediating the A. fumigatus induced increase in IL-33 expression in SNECs from patients with CRSwNP. METHODS: SNECs from CRSwNP patients were cultured and stimulated with various fungal components in the absence or presence of 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride, an irreversible serine protease inhibitor, or GB83, a reversible protease activated receptor 2 (PAR2) inhibitor. IL-33 expression was evaluated using quantitative real-time polymerase chain reaction (qRT-PCR). PAR2 expression was examined in inflamed mucosa from nonatopic control and CRSwNP patients. RESULTS: Elevation of IL-33 expression in primary SNECs was found in response to fungal protease but not fungal cell wall components. PAR2 expression was elevated in inflamed mucosa from CRSwNP patients in comparison to controls. The A. fumigatus fungal protease-mediated elevation in IL-33 expression by human SNECs was serine protease- and PAR2-dependent. CONCLUSION: These data suggest that serine protease activity of A. fumigatus is capable of inducing IL-33 expression in CRSwNP SNECs via PAR2, a potential therapeutic target in the treatment of CRSwNP. LEVEL OF EVIDENCE: NA Laryngoscope, 129:2230-2235, 2019.
Authors: Evan Li; Antony Rodriguez; Amber U Luong; David Allen; John Morgan Knight; Farrah Kheradmand; David B Corry Journal: Curr Opin Microbiol Date: 2021-05-27 Impact factor: 7.584
Authors: Hua Sun; Ashish Damania; Megan L Mair; Eniola Otukoya; Yi-Dong Li; Katherine Polsky; Yuying Zeng; Jeremiah A Alt; Martin J Citardi; David B Corry; Amber U Luong; John Morgan Knight Journal: Front Immunol Date: 2022-02-23 Impact factor: 7.561
Authors: Matthew A Tyler; Kent Lam; Michael J Marino; William C Yao; Isaac Schmale; Martin J Citardi; Amber U Luong Journal: Int Forum Allergy Rhinol Date: 2021-06-02 Impact factor: 3.858
Authors: Caroline M Percopo; Michelle Ma; Eric Mai; Jamie L Redes; Laura S Kraemer; Mahnaz Minai; Ian N Moore; Kirk M Druey; Helene F Rosenberg Journal: Viruses Date: 2020-08-27 Impact factor: 5.048
Authors: Ewen Mullins; Jean-Louis Bresson; Tamas Dalmay; Ian Crawford Dewhurst; Michelle M Epstein; Leslie George Firbank; Philippe Guerche; Jan Hejatko; Hanspeter Naegeli; Fabien Nogué; Nils Rostoks; Jose Juan Sánchez Serrano; Giovanni Savoini; Eve Veromann; Fabio Veronesi; Antonio Fernandez Dumont; Francisco Javier Moreno Journal: EFSA J Date: 2022-01-25